Compass Therapeutics 미래 성장

Future 기준 확인 2/6

Compass Therapeutics은 연간 수입과 매출이 각각 52.5%와 73.7% 증가할 것으로 예상되고 EPS는 연간 52.3%만큼 증가할 것으로 예상됩니다.

주요 정보

52.5%

수익 성장률

52.3%

EPS 성장률

Biotechs 수익 성장	28.3%
매출 성장률	73.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	20 Nov 2024

최근 미래 성장 업데이트

Recent updates

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

수익 및 매출 성장 예측

NasdaqCM:CMPX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	68	-69	N/A	-37	7
12/31/2025	5	-66	N/A	-46	7
12/31/2024	1	-49	N/A	-46	7
9/30/2024	1	-48	-48	-48	N/A
6/30/2024	1	-47	-43	-43	N/A
3/31/2024	N/A	-45	-42	-42	N/A
12/31/2023	N/A	-42	-41	-41	N/A
9/30/2023	N/A	-41	-39	-39	N/A
6/30/2023	N/A	-43	-44	-44	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-39	-34	-34	N/A
9/30/2022	N/A	-41	-29	-28	N/A
6/30/2022	N/A	-35	-22	-21	N/A
3/31/2022	N/A	-82	-24	-22	N/A
12/31/2021	N/A	-82	-22	-20	N/A
9/30/2021	N/A	-78	-23	-22	N/A
6/30/2021	N/A	-81	-26	-25	N/A
3/31/2021	N/A	-31	-25	-25	N/A
12/31/2020	N/A	-29	-27	-27	N/A
9/30/2020	N/A	-28	-26	-26	N/A
6/30/2020	N/A	-27	-26	-25	N/A
3/31/2020	N/A	-30	-29	-29	N/A
12/31/2019	N/A	-35	-32	-32	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CMPX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CMPX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CMPX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CMPX 의 수익(연간 73.7% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: CMPX 의 수익(연간 73.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CMPX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Compass Therapeutics 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates increase by 49%

Consensus revenue estimates increase by 32%

Price target decreased by 13% to US$8.00

Price target increased to US$9.46

Price target increased to US$9.67

Price target decreased to US$8.86

Recent updates

Consensus revenue estimates increase by 49%

New minor risk - Profitability

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 32%

Price target decreased by 13% to US$8.00

Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Index

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Compass Therapeutics, Inc. Announces Management Changes

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Compass Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

New minor risk - Shareholder dilution

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$80k worth of stock

Co-Founder recently bought US$77k worth of stock

Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit Committee

Price target increased to US$9.46

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy

President & COO recently sold US$97k worth of stock

Price target increased to US$9.67

High number of new and inexperienced directors

Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investors

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

High number of new and inexperienced directors

Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022

High number of new and inexperienced directors

Co-Founder recently bought US$61k worth of stock

Co-Founder recently bought US$50k worth of stock

Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

High number of new and inexperienced directors

Price target decreased to US$8.86

Compass Therapeutics Announces Management Appointments

Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Compass Therapeutics, Inc. Announces Resignation of Brett Kaplan of the Board of Directors

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

High number of new and inexperienced directors

Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견